歌礼制药(01672.HK)将发表两项肥胖症管线研究数据

阿斯达克财经
Nov 02

歌礼制药(01672.HK) 公布,其肥胖症管线口服小分子GIPR激动剂ASC48及GLP-1R/GIPR/GCGR三靶点激动剂多肽ASC37的两篇研究结果,将于今年11月14日至17日在美国华盛顿特区举行的2026年肥胖周中展示,是次将重点介绍ASC48有望成为同类首创的口服小分子GIPR激动剂,以及ASC37新一代每月一次至每季度一次三靶点激动剂多肽的临床前体外和体内数据。公司指,ASC37在...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10